Immix Biopharma opened lower at $8.40, compared with its previous close of $8.66. In the last trading session, the stock traded between $8.06 and $8.50. It showed a downward intraday trend.
An investment of $100 made 5 years ago in Immix Biopharma is now worth
$ 220.19
Giving a profit of
$ 120.19 (120.19%)
Note: Past profits do not guarantee future returns.
Rating from 5 Analysts
Today's Change
$-0.58 (-6.69%)
Day High
$8.50
Day Low
$8.06
Day Open
$8.40
Prev Close
$8.66
Volume
6,96,901
1W Return
1.58%
1M Return
-12.67%
3M Return
-29.64%
6M Return
-18.54%
1Y Return
150.19%
Market Cap ($ Mn)
670
PE Ratio
-
PB Ratio
4.34
PEG Ratio
-
ROE
-113.61%
ROCE
-111.42%
EPS (TTM)
$-0.15
1 Week
1.58%
1 Month
-12.67%
3 Months
-29.64%
6 Months
-18.54%
9 Months
18.14%
Immix Biopharma to present NXC-201 trial data at ASH 2026
Interim data for NXC-201 selected for oral presentation at ASH 2026. Presentation scheduled for December 14, 2026, in New Orleans. Trial covers 45 patients with relapsed/refractory AL amyloidosis. US patient population projected to reach 30,506 in 2026.
8 days agoIMMIX raises $3.5 million to expand stablecoin FX infrastructure
IMMIX raised $3.5 million from Crane Venture Partners, BTSE, and Portfolio Ventures. The firm uses AI pricing engines to facilitate stablecoin exchanges in non-dollar currencies. Systems have processed over $25 billion in customer trading volume since 2024. Funding will develop pricing technology, expand liquidity, and grow partner networks.
1mo agoImmix Biopharma closes $125M stock offering with $117.1M net proceeds
Immix Biopharma closed its $125 million underwritten offering on September 30, 2026. Net proceeds amounted to approximately $117.1 million after fees and expenses. Funds will support development of lead candidate NXC-201 and general corporate purposes. J.P. Morgan acted as the sole book-running manager for the transaction.
1mo agoPomerantz LLP probes Immix Biopharma over CMO fraud claims
Pomerantz LLP has initiated a securities fraud investigation into Immix Biopharma, Inc., focusing on the company's failure to disclose that former CMO Richard Graydon was actually fugitive Ronald L. Fischer. The stock dropped 14.15% on July 20, 2026, following revelations of his true identity. This adds to an existing probe by Schall, Brown & Schwartz LLP.
3mo agoNeedham initiates coverage on Immix Biopharma with Buy rating
Needham analyst Gil Blum initiates coverage on Immix Biopharma with a Buy rating and a price target of $21, signaling confidence in the NASDAQ-listed biopharmaceutical company.
3mo agoLaw firms investigate Immix Biopharma after executive termination
Holzer & Holzer and The Portnoy Law Firm are investigating Immix Biopharma regarding potential federal securities law violations following the termination of an executive allegedly operating under a false identity. Immix disclosed the termination on July 17, 2026, stating it was unrelated to company activities, while the stock price subsequently fell by roughly 10.83%.
3mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $547.03 | -0.16% | $1,38,692.89M | 31.55 | |
| $61.05 | +0.38% | $1,31,510.31M | 14.39 | |
| $248.69 | -0.85% | $1,00,625.20M | - | |
| $959.41 | +4.73% | $97,505.80M | 19.64 | |
| $977.58 | +0.62% | $61,476.10M | 38.99 | |
| $419.98 | -0.95% | $46,108.31M | 65.60 | |
| $180.70 | -6.40% | $39,083.96M | - | |
| $53.87 | -0.37% | $33,618.11M | 26.24 | |
| $70.01 | +0.81% | $31,173.07M | 32.37 | |
| $41.85 | +1.60% | $30,322.88M | - | |
| $120.75 | +1.05% | $26,490.14M | - | |
| $122.27 | +1.64% | $24,922.54M | 15.85 |
An investment of $100 made 5 years ago in Immix Biopharma is now worth
$ 220.19
Giving a profit of
$ 120.19 (120.19%)
Note: Past profits do not guarantee future returns.
